Trial Profile
Phase II Trial of Osimertinib in Combination With Stereotactic Ablative Radiation (SABR) in EGFR Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 May 2022 Planned End Date changed from 1 Apr 2022 to 1 Apr 2025.
- 13 May 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Apr 2024.
- 13 May 2022 Status changed from recruiting to active, no longer recruiting.